Garofalo Health Care S.p.A. (BIT:GHC) Analysts Are Pretty Bullish On The Stock After Recent Results
Last week, you might have seen that Garofalo Health Care S.p.A. (BIT:GHC) released its half-year result to the market. The early response was not positive, with shares down 5.7% to €5.30 in the past week. It was a credible result overall, with revenues of €267m and statutory earnings per share of €0.26 both in line with analyst estimates, showing that Garofalo Health Care is executing in line with expectations. The analyst typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analyst latest (statutory) post-earnings forecasts for next year.
Taking into account the latest results, the consensus forecast from Garofalo Health Care's one analyst is for revenues of €504.4m in 2026. This reflects an okay 2.1% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 17% to €0.25. Yet prior to the latest earnings, the analyst had been anticipated revenues of €504.4m and earnings per share (EPS) of €0.27 in 2026. The analyst seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.
View our latest analysis for Garofalo Health Care
Althoughthe analyst has revised their earnings forecasts for next year, they've also lifted the consensus price target 5.1% to €6.20, suggesting the revised estimates are not indicative of a weaker long-term future for the business.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Garofalo Health Care's revenue growth is expected to slow, with the forecast 4.3% annualised growth rate until the end of 2026 being well below the historical 14% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.3% annually. Factoring in the forecast slowdown in growth, it seems obvious that Garofalo Health Care is also expected to grow slower than other industry participants.
The Bottom Line
The most important thing to take away is that the analyst downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analyst believes the intrinsic value of the business is likely to improve over time.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for Garofalo Health Care going out as far as 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 2 warning signs for Garofalo Health Care you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.